Pancreatic Pseudocyst and Walled-off Necrosis Clinical Trial
Official title:
A Prospective, Multi-center, Single-arm Study to Evaluate the Safety and Efficacy of AXIOS Stent and Electrocautery-enhanced Delivery System in Chinese Patients With Pancreatic Pseudocyst and Walled-off Necrosis(WON)
| NCT number | NCT03808272 |
| Other study ID # | E7148 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | April 17, 2019 |
| Est. completion date | October 30, 2021 |
| Verified date | November 2023 |
| Source | Boston Scientific Corporation |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
To study the safety and effectiveness of the AXIOS Stent with Electrocautery Enhanced Delivery System for endoscopic trans enteric drainage of pancreatic pseudocyst and walled-off necrosis in Chinese population, to support the regulatory approval by CFDA
| Status | Completed |
| Enrollment | 31 |
| Est. completion date | October 30, 2021 |
| Est. primary completion date | December 24, 2020 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 75 Years |
| Eligibility | Inclusion Criteria: 1. Age between 18 and 75 years old(including 18 and 75 years old) 2. Eligible for endoscopic intervention 3. Acceptable candidate for endoscopic transluminal pancreatic pseudocyst drainage 4. Diagnostic as symptomatic pancreatic pseudocysts = 6cm in maximum diameter and walled-off necrosis = 6cm in maximum diameter with = 70% fluid content that are adherent to the gastric or bowel wall 5. Patient understands the study requirements and the treatment procedures and provides written Informed Consent. 6. Patient is willing to comply with all specified follow-up evaluations, including willingness to undergo a pre/post CT imaging study. Exclusion Criteria: 1. <18 or >75 years of age 2. pseudocysts or walled-off necrosis which require nasocystic drainage,or<6cm in maximum diameter, or walled-off necrosis < 70% fluid content 3. The fluid collection to be drained is an immature pseudocyst 4. The fluid collection to be drained is a cystic neoplasm 5. The fluid collection to be drained is a pseudoaneurysm 6. The fluid collection to be drained is a duplication cyst 7. The fluid collection to be drained is a non-inflammatory fluid collection 8. There is more than one pseudocyst requiring drainage 9. Abnormal coagulation: INR > 1.5 and not correctable presence of a bleeding disorder; platelets < 50,000/mm3 10. Altered anatomy that precludes the physician's ability to deliver the stent (decision on a case by case basis). 11. Intervening gastric varices or vessels within a one centimeter radius of the needle (visible using endoscopy or endoscopic ultrasound) 12. Any prior true anaphylactic reaction to contrast agents, nitinol (nickel titanium), silicone or any other materials contacting the patient. 13. Female of childbearing potential with a positive pregnancy test prior to the procedure or intends to become pregnant during the study. 14. Currently participating in another investigational drug of device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study. |
| Country | Name | City | State |
|---|---|---|---|
| China | Beijing Friendship Hospital, Capital Medical University | Beijing | Beijing |
| Lead Sponsor | Collaborator |
|---|---|
| Boston Scientific Corporation |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Technical success rate | defined as: placement of the AXIOS stent using the Electrocautery Enhanced AXIOS delivery system and removal of the AXIOS stent using a standard method: such as endoscopic snare or forceps. | 28± 7 days post stent placement | |
| Primary | Clinical success rate | defined as: at least a 50% decrease in pseudocyst's maximum diameter, based on radiographic analysis | 28± 7 days post stent placement |